Table 4 Literature review of studies on the efficacy of IFN-free regimens in hereditary bleeding disorder patients with HCV infection
Author | Study date | Study location | Sample size, n | Anti-HCV regimen, % | HCV genotype, % | Treatment naïve, % | HIV co-infection, % | Cirrhosis, % | SVR |
|---|---|---|---|---|---|---|---|---|---|
Fransen et al. [29] | 2019 | Belgium | 85 | SOF/LDV: 2.4% | NA* | 72.6 | NA* | 12 | 77/84 (91.6%) |
SOF/VEL: 16.4% | |||||||||
SOF + SIM: 5.9% | |||||||||
SOF + DCV: 12.9% | |||||||||
OBV/r/PTV ± DSV: 20.0% | |||||||||
EBR/GZR: 21.2% | |||||||||
GLE/PIB: 12.9% | |||||||||
Others**: 8.2% | |||||||||
Walsh et al. [3] | 2017 | US | 120 | SOF/LDV: 86.7% | 1: 0.8% | 60 | 21.7% | 30.8 | 118/120 (98.3%) |
SOF + RBV: 13.3% | 1a: 59.2% | ||||||||
1b: 25.9% | |||||||||
2: 8.3% | |||||||||
3: 5% | |||||||||
4: 0.8% | |||||||||
Nagao et al. [31] | 2017 | Japan | 43 | SOF/LDV: 100% | 1a: 58.1% | 58.1 | 46.5% | 20.9 | 41/43 (95.3%) |
1b: 27.9% | |||||||||
1a + 2b: 2.3% | |||||||||
4: 11.7% | |||||||||
Lee et al. [7] | 2017 | Korea | 30 | DCV + ASV: 60% | 1b: 70% | 70 | NR | 13.3 | 28/30 (93.3%) |
LDV/SOF: 26.7% | 1a: 16.7% | ||||||||
SOF + RBV: 13.3% | 2a/2b: 13.3% | ||||||||
Stedman et al. [32] | 2016 | New Zealand | 14 | SOF/LDV + RBV: 100% | 1a: 71% | 79 | 0% | 7 | 14/14 (100%) |
1b: 29% | |||||||||
Mancuso et al. [17] | 2020 | Italy | 200 | SOF/VEL: 22.5% | 1a: 63% | 54 | 20% | 28 | 198/200 (99%) |
GLE/PIB: 20% | 1b: 15% | ||||||||
SOF/LDV: 11.5% | 1: 1% | ||||||||
SOF/LDV + RBV: 10% | 2: 12% | ||||||||
SOF + SIM: 6.5% | 3: 7% | ||||||||
GZR/EBR: 6.5% | 4: 3% | ||||||||
DSV/PTV/OBV/r: 5.5% | |||||||||
DSV/PTV/OBV/r + RBV: 5% | |||||||||
SOF + DCV + RBV: 4% | |||||||||
DCV + RBV: 2.5% | |||||||||
SOF + DCV: 2% | |||||||||
SOF + RBV: 1.5% | |||||||||
SOF/VEL + RBV: 1.5% | |||||||||
SOF + SIM + RBV: 1% | |||||||||
Xiao et al. [34] | 2019 | China | 12 | SOF + DCV: 66.7% | 1b: 75% | 41.7 | 100% | 33 | 12/12 (100%) |
SOF/VEL: 16.7% | 2i: 16.7% | ||||||||
SOF + RBV: 8.3% | 3: 8.3% | ||||||||
DCV + ASV: 8.3% | |||||||||
Uemura et al. [33] | 2017 | Japan | 27 | SOF/LDV: 85.2% | 1a: 15% | 33 | 100% | 41 | 27/27 (100%) |
SOF + RBV: 3.7% | 1b: 59% | ||||||||
SOF + DCV: 11.1% | 1: 7% | ||||||||
2a: 4% | |||||||||
3a: 11% | |||||||||
4a: 4% | |||||||||
Guedes et al. [30] | 2020 | Portugal | 16 | SOF/LDV: 75% | 1a: 40% | 12.5 | NR | 62.5 | 16/16 (100%) |
SOF/LDV + RBV: 6.25% | 1b:46.6% | ||||||||
SOF + RBV: 6.25% | 2: 6.7% | ||||||||
OBV/PTV/r + DSV: 6.25% | 3a: 6.7% | ||||||||
EBR/GZR: 6.25% | |||||||||
Current study | 2020 | Iran | 147 | SOF/LDV: 27.9% | 1: 68.1% | 46.3 | 4.1% | 25.2 | 132/132 (100%) |
SOF/LDV + RBV: 36.1% | 2: 1.4% | ||||||||
SOF/DCV: 17.7% | 3: 20.8% | ||||||||
SOF/DCV + RBV: 12.2% | 4: 2.8% | ||||||||
SOF/VEL: 5.4% | Mix: 6.9% | ||||||||
SOF + RBV: 0.7% |